See more : Sadot Group Inc. (SDOT) Income Statement Analysis – Financial Results
Complete financial analysis of Inovio Pharmaceuticals, Inc. (INO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inovio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Coastal Financial Corporation (CCB) Income Statement Analysis – Financial Results
- Harvest Technology Group Limited (HTG.AX) Income Statement Analysis – Financial Results
- Qell Acquisition Corp. (QELL) Income Statement Analysis – Financial Results
- TBN Corporation Public Company Limited (TBN.BK) Income Statement Analysis – Financial Results
- Nickel Rock Resources Inc. (NICL.V) Income Statement Analysis – Financial Results
Inovio Pharmaceuticals, Inc. (INO)
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 832.01K | 10.26M | 1.77M | 7.41M | 4.11M | 30.48M | 42.22M | 35.37M | 40.57M | 10.46M | 13.47M | 4.12M | 9.80M | 6.14M | 9.12M | 2.10M | 4.81M | 3.47M | 5.47M | 1.17M | 80.53K | 189.52K | 4.45M | 5.08M | 8.30M |
| Cost of Revenue | 3.50M | 5.50M | 4.73M | 94.25M | 88.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 225.00K | 206.25K | 0.00 | 0.00 | 0.00 | 1.93M | 1.46M | 1.20M |
| Gross Profit | -2.67M | 4.77M | -2.96M | -86.83M | -83.91M | 30.48M | 42.22M | 35.37M | 40.57M | 10.46M | 13.47M | 4.12M | 9.80M | 6.14M | 9.12M | 2.10M | 4.81M | 3.24M | 5.26M | 1.17M | 80.53K | 189.52K | 2.53M | 3.62M | 7.10M |
| Gross Profit Ratio | -321.09% | 46.44% | -166.56% | -1,171.66% | -2,040.54% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 93.51% | 96.23% | 100.00% | 100.00% | 100.00% | 56.77% | 71.29% | 85.54% |
| Research & Development | 86.68M | 187.65M | 249.24M | 94.25M | 88.02M | 95.26M | 98.57M | 88.71M | 57.79M | 34.10M | 21.37M | 17.98M | 20.03M | 13.26M | 9.41M | 5.75M | 9.63M | 8.51M | 11.45M | 6.55M | 2.15M | 2.47M | 459.71K | 6.98M | 8.10M |
| General & Administrative | 47.58M | 90.19M | 53.75M | 37.25M | 27.20M | 29.32M | 28.29M | 23.89M | 18.06M | 15.86M | 13.64M | 10.78M | 11.99M | 12.11M | 13.67M | 10.01M | 11.08M | 8.08M | 5.98M | 6.13M | 4.57M | 3.66M | 0.00 | 5.61M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.58M | 90.19M | 53.75M | 37.25M | 27.20M | 29.32M | 28.29M | 23.89M | 18.06M | 15.86M | 13.64M | 10.78M | 11.99M | 12.11M | 13.67M | 10.01M | 11.08M | 8.08M | 5.98M | 6.13M | 4.57M | 3.66M | 6.62M | 5.61M | 5.50M |
| Other Expenses | -1.70M | -3.86M | 343.37K | 3.42M | 496.20K | 360.80K | 806.82K | 127.55K | 177.56K | 348.14K | -45.63M | 1.98M | 0.00 | 0.00 | 9.28M | 4,672.53B | 7,547.58B | 225.00K | 206.25K | 5.60M | 2.07M | 2.28M | 0.00 | 566.36K | 400.00K |
| Operating Expenses | 132.56M | 277.84M | 302.99M | 131.49M | 115.22M | 124.57M | 126.86M | 112.60M | 75.86M | 49.95M | 35.01M | 28.76M | 32.02M | 25.36M | 23.08M | 15.76M | 20.71M | 16.81M | 17.64M | 12.68M | 6.71M | 6.12M | 7.08M | 13.15M | 14.00M |
| Cost & Expenses | 144.77M | 277.84M | 302.99M | 131.49M | 115.22M | 124.57M | 126.86M | 112.60M | 75.86M | 49.95M | 35.01M | 28.76M | 32.02M | 25.36M | 23.08M | 15.76M | 20.71M | 16.81M | 17.64M | 12.68M | 6.71M | 6.12M | 9.01M | 14.61M | 15.20M |
| Interest Income | 8.13M | 4.78M | 3.36M | 3.31M | 2.61M | 2.26M | 1.61M | 1.40M | 305.07K | 0.00 | 132.21K | 166.11K | 0.00 | 0.00 | 0.00 | 0.00 | 1.27M | 867.07K | 207.68K | 247.56K | 65.50K | 32.32K | 443.63K | 556.19K | 556.19K |
| Interest Expense | 1.22M | 1.25M | 1.94M | 8.70M | 7.95M | 346.09K | 4.56M | 139.25K | 0.00 | 0.00 | 88.17M | 0.00 | 34.29K | 0.00 | 10.50M | 0.00 | 0.00 | 0.00 | 3.33M | 0.00 | 20.48K | 5.45K | -20.38K | 24.34K | 24.34K |
| Depreciation & Amortization | 3.50M | 5.50M | 4.73M | 4.63M | 5.52M | 5.00M | 3.47M | 3.09M | 1.92M | 1.57M | 2.10M | 1.99M | 2.01M | 2.11M | 1.68M | 993.03K | 954.64K | 911.64K | 799.32K | 573.04K | 584.41K | 619.34K | 0.00 | 566.36K | 400.00K |
| EBITDA | -130.39M | -270.90M | -296.56M | -149.56M | -107.34M | -89.80M | -84.74M | -74.15M | -33.37M | -37.93M | -19.45M | -22.65M | -21.64M | -17.11M | -13.96M | -11.97M | -10.19M | -12.43M | -11.38M | -10.94M | -6.05M | -5.28M | -5.58M | -8.37M | -8.97M |
| EBITDA Ratio | -15,671.81% | -2,616.89% | -16,528.13% | -1,027.76% | -2,567.66% | -293.47% | -196.54% | -212.84% | -85.14% | -366.03% | 179.60% | -626.01% | -301.08% | -318.79% | -120.85% | -606.13% | -382.00% | -358.53% | -147.17% | -937.17% | -7,511.39% | -2,787.69% | -125.22% | -164.87% | -81.93% |
| Operating Income | -135.23M | -267.57M | -301.22M | -124.08M | -111.11M | -94.09M | -83.64M | -76.24M | -34.28M | -39.50M | -19.54M | -23.49M | -21.64M | -19.22M | -13.96M | -13.66M | -15.90M | -13.35M | -15.51M | -11.51M | -6.63M | -5.93M | -5.58M | -9.53M | -6.90M |
| Operating Income Ratio | -16,253.01% | -2,607.35% | -16,972.34% | -1,674.25% | -2,702.10% | -308.68% | -198.11% | -215.55% | -84.50% | -377.71% | -145.12% | -570.42% | -220.91% | -312.79% | -153.04% | -651.14% | -330.68% | -384.82% | -283.63% | -986.27% | -8,237.11% | -3,131.53% | -125.22% | -187.79% | -83.13% |
| Total Other Income/Expenses | 109.31K | -10.08M | -2.01M | -38.81M | -9.70M | -706.88K | -4.56M | 2.50M | 3.08M | 3.36M | -46.54M | 3.78M | 6.33M | 1.51M | -10.50M | 692.84K | 3.42M | 867.07K | 2.44K | 247.56K | 6.63M | 26.87K | -3.29M | -597.18K | 2.93M |
| Income Before Tax | -135.12M | -277.65M | -303.22M | -162.89M | -120.81M | -94.80M | -88.21M | -73.74M | -31.20M | -36.14M | -66.08M | -19.71M | -12.95M | -17.71M | -24.46M | -13.61M | -12.48M | -14.48M | -15.50M | -0.66 | -0.43 | -5.91M | -8.87M | -10.13M | -6.60M |
| Income Before Tax Ratio | -16,239.87% | -2,705.57% | -17,085.39% | -2,197.89% | -2,938.01% | -311.00% | -208.92% | -208.49% | -76.90% | -345.61% | -490.69% | -478.63% | -132.19% | -288.27% | -268.21% | -648.80% | -259.52% | -417.65% | -283.59% | 0.00% | 0.00% | -3,117.36% | -199.11% | -199.55% | -79.52% |
| Income Tax Expense | 0.00 | 10.01M | 2.16M | 52.20M | -257.34K | 2.17M | 1.76M | -4.62M | -2.10M | -3.72M | 88.12M | -8.11M | -16.28M | -4.08M | 11.71M | -741.85K | -8.12M | -867.07K | 6.45M | -537.76K | -1.99M | 56.78K | 0.00 | 638.17K | -600.00K |
| Net Income | -135.12M | -287.66M | -305.38M | -215.09M | -120.55M | -96.97M | -88.21M | -73.74M | -29.19M | -36.12M | -66.03M | -19.67M | -15.25M | -17.61M | -24.41M | -12.97M | -11.20M | -12.48M | -15.30M | -10.97M | -4.66M | -5.96M | -8.87M | -9.60M | -6.60M |
| Net Income Ratio | -16,239.87% | -2,803.13% | -17,207.13% | -2,902.17% | -2,931.76% | -318.12% | -208.92% | -208.49% | -71.94% | -345.44% | -490.29% | -477.56% | -155.72% | -286.65% | -267.67% | -618.11% | -233.05% | -359.82% | -279.79% | -940.19% | -5,792.83% | -3,147.32% | -199.11% | -189.07% | -79.52% |
| EPS | -6.09 | -14.47 | -17.55 | -16.64 | -14.65 | -1.05 | -1.08 | -1.01 | -0.43 | -0.61 | -1.43 | -0.58 | -0.48 | -0.68 | -1.31 | -1.18 | -1.08 | -1.58 | -3.22 | -2.49 | -1.40 | -2.35 | -5.13 | -6.80 | -5.21 |
| EPS Diluted | -6.09 | -14.47 | -17.55 | -16.64 | -14.65 | -1.05 | -1.08 | -1.01 | -0.43 | -0.61 | -1.43 | -0.58 | -0.48 | -0.68 | -1.31 | -1.18 | -1.08 | -1.58 | -3.22 | -2.49 | -1.40 | -2.35 | -5.13 | -6.80 | -5.21 |
| Weighted Avg Shares Out | 22.17M | 19.89M | 17.40M | 12.93M | 8.23M | 92.35M | 81.78M | 73.01M | 68.20M | 59.13M | 46.09M | 33.91M | 31.56M | 25.80M | 18.68M | 10.98M | 10.37M | 7.88M | 4.75M | 4.41M | 3.33M | 2.54M | 1.73M | 1.41M | 1.27M |
| Weighted Avg Shares Out (Dil) | 22.17M | 19.89M | 17.40M | 12.93M | 8.23M | 92.54M | 81.92M | 73.21M | 68.37M | 59.41M | 46.09M | 34.13M | 31.56M | 25.80M | 18.68M | 10.98M | 10.37M | 7.88M | 4.75M | 4.41M | 3.33M | 2.54M | 1.73M | 1.41M | 1.27M |
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
INOVIO Reports Inducement Grant Under Inducement Plan
INOVIO Added to Russell 2000® Index Effective July 1, 2024
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
INOVIO Reports Inducement Grants Under Inducement Plan
Better Buy: Inovio Pharmaceuticals vs. Novavax
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference (Transcript)
Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)
Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)
Source: https://incomestatements.info
Category: Stock Reports